Every Perlara program starts with a specific conversation — a family, a foundation, an academic lab, or a pharma partner who sees an inherited metabolic disease that has been waiting too long for a therapy. Tell us which one you’re here for.
If your family or foundation is focused on a single inherited metabolic disease — especially CDGs, mitochondrial, GPI-anchor, or tRNA-synthetase disorders — we can scope a yeast avatar and a screening run as the first chapter of a Cure Odyssey. Treatment-naïve genes welcome.
We collaborate with academic labs on humanized yeast avatars, patient-cell validation, and mechanism-of-action studies. We’re especially open to groups with patient-derived fibroblasts, iPSCs, or organoids that need a fast pharmacology layer.
Several Perlara programs are at IND-enabling readiness. We out-license assets where a partner can move faster on development and commercialization than we can solo, retaining patient-foundation rights and Cure Odysseys narration access.
Press kit, founder bio, and investor briefing materials are available on request. We host quarterly Cure Odysseys live updates — ask to be added to the invite list.
Use the form below or email info@perlara.com directly. We read every message and respond within two business days.